The laws establishing the US biosimilar approval pathway were passed in 2010, but the market for biosimilars is only beginning to gain speed. The causes for this slow start are complex and multifactorial. Veteran biosimilar industry journalist Stanton Mehr unravels the competing interests of stakeholders and pragmatically reframes the conversation: How did we arrive at today’s biosimilar marketplace? What biosimilar drug categories will thrive or fail? What dynamic forces may drive a biosimilar future in the US?
The report, Where the US Biosimilars Market Is Heading and When It Might Get There, is a vital resource for those managing drug benefits, designing medical and pharmacy coverage policies, prescribing biologic medications, and the manufacturers of biosimilars and biologics alike.
This 74-page report covers the past, present, and future of the US biosimilar industry. We take an in-depth view into five critical drug categories. We delineate the forcing factors that will allow for future success of biosimilars in the America. This publication also analyzes the competing priorities of each relevant stakeholder, some of which can limit or optimize the biosimilar-related savings obtained by the US health system.